Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways

Hormone and Metabolic Research

Volumn 46, Issue 11, 2014, Pages 753-760

  Zhou, R ^a   Xu, L ^b   Ye, M ^c   Liao, M ^c   Du, H ^a   Chen, H ^c  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

breast cancer; formononetin; matrix metalloproteinases; migration; PI3K AKT

Indexed keywords

FORMONONETIN; GELATINASE A; GELATINASE B; ISOFLAVONE DERIVATIVE; LUCIFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL DEATH; CELL MOTION; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HUMAN; LUNG NEOPLASMS; METABOLISM; NEOPLASM INVASIVENESS; NUDE MOUSE; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; ISOFLAVONES; LUCIFERASES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84923912078     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1376977     Document Type: Article

References (56)

1. Redig A. J., McAllister S. S. Breast cancer as a systemic disease: a view of metastasis. J Intern Med: 2013; 274 113 126
2. Mahamodhossen Y. A., Liu W., Rong-Rong Z. Triple-negative breast cancer: new perspectives for novel therapies. Med Oncol: 2013; 30 653
3. Amos K. D., Adamo B., Anders C. K. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer: 2012; 2012 385978
4. Baser O., Wei W., Xie L., Henk H. J., Teitelbaum A. Retrospective study of patients with metastatic triple-negative breast cancer: survival, health care utilization, and cost. Comm Oncol: 2012; 9 8 14
5. Talvensaari-Mattila A., Paakko P., Hoyhtya M., Blanco-Sequeiros G., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer: 1998; 83 1153 1162
6. Pellikainen J. M., Ropponen K. M., Kataja V. V., Kellokoski J. K., Eskelinen M. J., Kosma V. M. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clinical cancer research: 2004; 10 7621 7628
7. Li H. C., Cao D. C., Liu Y., Hou Y. F., Wu J., Lu J. S., Di G. H., Liu G., Li F. M., Ou Z. L., Jie C., Shen Z. Z., Shao Z. M. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat: 2004; 88 75 85
8. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer: 2002; 2 161 174
9. Li W., Sun Y. N., Yan X. T., Yang S. Y., Kim S., Lee Y. M., Koh Y. S., Kim Y. H. Flavonoids from Astragalus membranaceus and their inhibitory effects on LPS-stimulated pro-inflammatory cytokine production in bone marrow-derived dendritic cells. Arch Pharm Res: 2014; 37 186 192
10. Ma Z., Ji W., Fu Q., Ma S. Formononetin Inhibited the Inflammation of LPS-Induced Acute Lung Injury in Mice Associated with Induction of PPAR Gamma Expression. Inflammation: 2013; 36 1560 1566
11. Lai P. K., Chan J. Y., Cheng L., Lau C. P., Han S. Q., Leung P. C., Fung K. P., Lau C. B. Isolation of anti-inflammatory fractions and compounds from the root of Astragalus membranaceus. Phytother Res: 2013; 27 581 587
12. Ren J., Xu H. J., Cheng H., Xin W. Q., Chen X., Hu K. Synthesis and antitumor activity of Formononetin nitrogen mustard derivatives. Eur J Med Chem: 2012; 54 175 187
13. Ji Z. N., Zhao W. Y., Liao G. R., Choi R. C., Lo C. K., Dong T. T., Tsim K. W. In vitro estrogenic activity of Formononetin by two bioassay systems. Gynecological endocrinology: the official journal of the International Society of Gynecol Endocrinol: 2006; 22 578 584
14. Park J., Kim S. H., Cho D., Kim T. S. Formononetin, a phyto-oestrogen, and its metabolites up-regulate interleukin-4 production in activated T cells via increased AP-1 DNA binding activity. Immunology: 2005; 116 71 81
15. Sun T., Wang J., Huang L. H., Cao Y. X. Antihypertensive effect of Formononetin through regulating the expressions of eNOS, 5-HT2A/1B receptors and alpha1-adrenoceptors in spontaneously rat arteries. Eur J Pharmacol: 2013; 699 241 249
16. Ye Y., Hou R., Chen J., Mo L., Zhang J., Huang Y., Mo Z. Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation. Horm Metab Res: 2012; 44 263 267
17. Chen J., Zeng J., Xin M., Huang W., Chen X. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm Metab Res: 2011; 43 681 686
18. Chen J., Sun L. Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells. Horm Metab Res: 2012; 44 943 948
19. Mansoor T. A., Ramalho R. M., Luo X., Ramalhete C., Rodrigues C. M., Ferreira M. J. Isoflavones as apoptosis inducers in human hepatoma HuH-7 cells. Phytother Res: 2011; 25 1819 1824
20. Auyeung K. K., Law P. C., Ko J. K. Novel anti-angiogenic effects of Formononetin in human colon cancer cells and tumor xenograft. Oncol Rep: 2012; 28 2188 2194
21. Krenn L., Paper D. H. Inhibition of angiogenesis and inflammation by an extract of red clover (Trifolium pratense L.). Phytomedicine: 2009; 16 1083 1088
22. Chavez K. J., Garimella S. V., Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis: 2010; 32 35 48
23. Heppner G. H., Miller F. R., Shekhar P. M. Nontransgenic models of breast cancer. Breast Cancer Res: 2000; 2 331 334
24. Tao K., Fang M., Alroy J., Sahagian G. G. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer: 2008; 8 228
25. Tyagi A. M., Srivastava K., Singh A. K., Kumar A., Changkija B., Pandey R., Lahiri S., Nagar G. K., Yadav D. K., Maurya R., Trivedi R., Singh D. Formononetin reverses established osteopenia in adult ovariectomized rats. Menopause (New York, NY): 2012; 19 856 863
26. Scully O. J., Bay B. H., Yip G., Yu Y. Breast cancer metastasis. Cancer Genom Proteom: 2012; 9 311 320
27. Alix-Panabieres C., Muller V., Pantel K. Current status in human breast cancer micrometastasis. Curr Opin Oncol: 2007; 19 558 563
28. Deryugina E. I., Quigley J. P. Matrix metalloproteinases and tumor metastasis. Cancer Metas Rev: 2006; 25 9 34
29. Jezierska A., Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Mon: 2009; 15 RA32 RA40
30. Vizoso F. J., Gonzalez L. O., Corte M. D., Rodriguez J. C., Vazquez J., Lamelas M. L., Junquera S., Merino A. M., Garcia-Muniz J. L. Study of matrix metalloproteinases and their inhibitors in breast cancer. Brit J Cancer: 2007; 96 903 911
31. Hua J., Muschel R. J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer research: 1996; 56 5279 5284
32. Kondraganti S., Mohanam S., Chintala S. K., Kin Y., Jasti S. L., Nirmala C., Lakka S. S., Adachi Y., Kyritsis A. P., Ali-Osman F., Sawaya R., Fuller G. N., Rao J. S. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer research: 2000; 60 6851 6855
33. Iurlaro M., Loverro G., Vacca A., Cormio G., Ribatti D., Minischetti M., Ria R., Bruno M., Selvaggi L. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest: 1999; 29 793 801
34. Cruz-Munoz W., Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci: 2008; 45 291 338
35. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Nat Cancer Inst: 1994; 86 299 304
36. Khokha R., Zimmer M. J., Graham C. H., Lala P. K., Waterhouse P. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Nat Cancer Inst: 1992; 84 1017 1022
37. Valente P., Fassina G., Melchiori A., Masiello L., Cilli M., Vacca A., Onisto M., Santi L., Stetler-Stevenson W. G., Albini A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer: 1998; 75 246 253
38. Chen J. S., Wang Q., Fu X. H., Huang X. H., Chen X. L., Cao L. Q., Chen L. Z., Tan H. X., Li W., Bi J., Zhang L. J. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res: 2009; 39 177 186
39. Li X., Yang Z., Song W., Zhou L., Li Q., Tao K., Zhou J., Wang X., Zheng Z., You N., Dou K., Li H. Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway. Int J Oncol: 2013; 43 793 802
40. Tian T., Nan K. J., Guo H., Wang W. J., Ruan Z. P., Wang S. H., Liang X., Lu C. X. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol Rep: 2010; 23 1593 1600
41. Qiu Q., Yang M., Tsang B. K., Gruslin A. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction: 2004; 128 355 363
42. Ye B., Jiang L. L., Xu H. T., Zhou D. W., Li Z. S. Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. Int J Immunopathol Pharmacol: 2012; 25 627 636
43. Huang C. Y., Fong Y. C., Lee C. Y., Chen M. Y., Tsai H. C., Hsu H. C., Tang C. H. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol: 2009; 77 794 803
44. Zhang Z. J., Ma S. L. miRNAs in breast cancer tumorigenesis (Review). Oncol Rep: 2012; 27 903 910
45. Jung C. H., Kim E. M., Park J. K., Hwang S. G., Moon S. K., Kim W. J., Um H. D. Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol Rep: 2013; 29 2109 2113
46. Xie Y., Abel P. W., Kirui J. K., Deng C., Sharma P., Wolff D. W., Toews M. L., Tu Y. Identification of upregulated phosphoinositide 3-kinase gamma as a target to suppress breast cancer cell migration and invasion. Biochem Pharmacol: 2013; 85 1454 1462
47. Karam A. K., Santiskulvong C., Fekete M., Zabih S., Eng C., Dorigo O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton: 2010; 67 535 544
48. Chen J., Lan T., Hou J., Zhang J., An Y., Tie L., Pan Y., Liu J., Li X. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1. Int J Biochem Cell Biol: 2012; 44 759 769
49. Ko H. S., Lee H. J., Kim S. H., Lee E. O. Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-kappaB pathways. J Agric Food Chem: 2012; 60 4083 4089
50. Lee H., Kim J. S., Kim E. Fucoidan from seaweed Fucus vesiculosus inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways. PloS One: 2012; 7 e50624
51. Hsieh C. Y., Tsai P. C., Chu C. L., Chang F. R., Chang L. S., Wu Y. C., Lin S. R. Brazilein suppresses migration and invasion of MDA-MB-231 breast cancer cells. Chemicobiol Interact: 2013; 204 105 115
52. Tang L., Ma X., Tian Q., Cheng Y., Yao H., Liu Z., Qu X., Han X. Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells. Food Chem Toxicol: 2013; 56 204 213
53. Tong B., Lu D., Wei Z., Wang T., Xia Y., Dai Y. Gleditsioside B, a triterpene saponin isolated from the anomalous fruits of Gleditsia sinensis Lam., abrogates bFGF-induced endothelial cell migration through preventing the activation of MMP-2 and FAK via inhibiting ERK and PI3K/AKT signaling pathways. Vascul Pharmacol: 2013; 58 118 126
54. Yan K. H., Lee L. M., Yan S. H., Huang H. C., Li C. C., Lin H. T., Chen P. S. Tomatidine inhibits invasion of human lung adenocarcinoma cell A549 by reducing matrix metalloproteinases expression. Chemico-biological interactions: 2013; 203 580 587
55. Chen S. M., Liu J. L., Wang X., Liang C., Ding J., Meng L. H. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. Biochem Pharmacol: 2012; 83 1183 1194
56. Li M., Wu S., Liu Z., Zhang W., Xu J., Wang Y., Liu J., Zhang D., Tian H., Li Y., Ye W. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochem Pharmacol: 2012; 83 1251 1260